Clinical trial
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease…
NCT02344290 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT02344290 |
|---|---|
| Title | Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults |
| Official title | Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE |
| Acronym | REPRIEVE |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH Kowa Pharmaceuticals America, Inc. Industry Gilead Sciences Massachusetts General Hospital NEAT ID Foundation |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV, Cardiovascular Diseases |
| Intervention type | Drug |
| Interventions | Pitavastatin, Placebo |
| Enrollment | 7,769 |
| Start date | Mar 26, 2015 |
| Primary completion | Aug 21, 2023 |
| Completion | Aug 21, 2023 |
| First posted | Jan 22, 2015 |
| Last update posted | Sep 4, 2025 |
| Countries | Botswana, Brazil, Canada, Haiti, India, Peru, Puerto Rico, South Africa, Spain, Thailand, Uganda, United States and 1 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: